ContextVision – Strong Q3 with solid sales, good inflow of new customers and first product in digital pathology enters beta-testing phase

ContextVision, Financial reports, Home, Investor News, News 2019-10-24
ContextVision has seen a strong third quarter in 2019 as new customers have been added and the first product in digital pathology has entered the beta-testing phase. Q3 sales reached 23 MSEK and total sales are growing +5% compared to the third quarter last year. The operating result was positive 4.6 MSEK.
Read More

ContextVision AB – Company presentation held in Oslo

Investor News 2019-09-18
Stockholm, September 18th, 2019 – Today ContextVision held a company presentation in Oslo, Norway. The arrangement was held at Norne Securities AS premises at Roald Amundsens gt. 6, Oslo. CEO Fredrik Palm gave an update of the company’s development and shared the company’s future direction. Please find a PDF-version of the presentation attached. The presentation […]
Read More

ContextVision – Company presentations held at Danske Bank Small Cap Day in Stockholm

Investor News 2019-09-12
Stockholm, September 12th, 2019 – Today ContextVision presented the company at Danske Bank’s Small Cap Day in Stockholm, Sweden. CEO Fredrik Palm gave an update of the company’s development and shared the company’s future direction. Please find a PDF-version of the presentation attached. The presentation will also be published on the company’s website. For further […]
Read More

ContextVision AB – Invitation to company presentation

Investor News 2019-09-11
We are pleased to invite you to a presentation of Contextvision AB and its 2nd quarter and six months 2019 figures and give an update on the ongoing projects. The meeting will be held at the offices of Norne Securities AS (Oslo Office), Roald Amundsens gt. 6, Oslo. Wednesday, September 18th at 12.00 Lunch will […]
Read More

ContextVision – Second quarter saw commercial release of first AI-based product, Altumira™, Digital Pathology on track and record sales

Financial reports, Home, Investor News, News 2019-08-15
ContextVision’s AI-based product Altumira™ for X-ray is now commercially available and INIFY Prostate for digital pathology will soon move to beta testing in several pathology labs. Q2 sales reached 23,1 MSEK, record sales for second quarter, 5,5% higher than Q2 2018. The operating result was positive 5,4 MSEK, mainly due to higher capitalization for product development but also supported by strong sales performance.
Read More

Company presentation held at Carnegie in Stockholm

Investor News 2019-06-12
Stockholm, June 12th, 2019 – Today ContextVision held a company presentation at Carnegie in Stockholm, Sweden. Fredrik Palm gave an update of the company’s development and shared the company’s future direction. Please find a PDF-version of the presentation here. For further information, please contact ContextVision’s CEO, Fredrik Palm, at +46 76 870 25 43 or […]
Read More

ContextVision stock-based incentive program – share transactions

Investor News 2019-05-29
Stockholm, May 29, 2019   The ContextVision AB:s Profit Sharing Foundation has sold and purchased shares in ContextVision AB in accordance with the rules related to the foundation.   The ContextVision AB:s Profit Sharing Foundation has sold 23,700 shares during the period April 3 – May 23, at an average price of 72,35 NOK/share, in […]
Read More

ContextVision – Annual General Meeting 2019

Investor News 2019-05-09
On the 8th of May 2019, ContextVision held its ordinary Shareholders’ Annual General Meeting in Stockholm.   The annual financial report regarding 2018 was presented and approved by the AGM. Disposition of financial results according to the proposal of the Board of Directors was approved. The Managing Director and the Board of Directors were discharged […]
Read More